Table 5 Comparisons of LDLC change among PCSK9 inhibitor treatment groups and between statin tolerant and intolerant groups
|  | Alirocumab 75 mg (n = 25) | Alirocumab 150 mg (n = 15) | Evolucumab 140 mg (n = 32) |
LS means ± SE of change in LDLC (mg/dl) | −59 ± 10 | −110 ± 14 | −95 ± 9 |
 Group differences | ALI 75 vs ALI 150, p = .004 | ||
ALI 75 vs EVO 140, p = .014 | |||
LS means ± SE of % change in LDLC (%) | −42 ± 5% | −63 ± 7% | −56 ± 4% |
 Group differences | ALI 75 vs ALI 150, p = .011 | ||
ALI 75 vs EVO 140, p = .044 | |||
LS means ± SE of change in LDLC (mg/dl) | −109 ± 7 | −78 ± 5 | |
Group differences | p = .0008 | ||
LS means ± SE of % change in LDLC (%) | −63 ± 5% | −48 ± 4% | |
Group differences | p = .013 | ||